



SCHOLARONE™
Manuscripts

Virgin olive oil enriched with its own phenolics or complemented with thyme phenols improves DNA protection against oxidation and antioxidant enzyme activity in hyperlipidemic subjects

Marta Romeu[†], Laura Rubió[‡], Vanessa Sánchez-Martos[†], Olga Castañer[§], Rafael de la Torre[§], Rosa M Valls[†], Rosa Ras[†], Anna Pedret[†], Úrsula Catalán[†], María del Carmen López de las Hazas[‡], María J Motilva^{*‡}, Montserrat Fitó[§], Rosa Solà^{*†}, Montserrat Giralt[†]

[†] Pharmacology Unit, Department of Basic Medical Sciences, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, NFOC group, C/ Sant Llorenç 21, 43201 Reus (Spain). marta.romeu@urv.cat; vanessa.sanchez@urv.cat; montse.giralt@urv.cat

[‡] Food Technology Department, UTPV-XaRTA, Universitat de Lleida- Agrotecnio Research Center, C. Alcalde Rovira Roure 191, 25198 Lleida (Spain). laura.rubio@iispv.cat; mclopez@tecal.udl.cat; motilva@tecal.udl.cat

[§] Cardiovascular Risk and Nutrition Research Group, CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, C. Doctor Aiguader 88, 08003 Barcelona (Spain). ocastaner@imim.es; RTorre@imim.es; MFito@imim.es

[†] Unitat de Recerca en Lípids i Arteriosclerosi, CIBERDEM, St. Joan de Reus University Hospital, CTNS, IISPV, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, NFOC Group, C. Sant Llorenç 21, 43201 Reus (Spain). rosamaria.valls@urv.cat; anna.pedret@urv.cat; ursula.catalan@urv.cat; rosa.sola@urv.cat

[‡] Center for Omics Sciences, Avda. Universitat n° 1, 43204, Reus (Spain).

mariarosa.ras@urv.cat

Corresponding authors:

Rosa Solà, MD, PhD

e-mail: rosa.sola@urv.cat

Tel. +34 977 759369

Fax. +34 977 759378

Dept Medicina i Cirurgia, Universitat Rovira i Virgili

Sant Llorenç 21, 43201 Reus (Spain)

Maria José Motilva, PhD

e-mail: motilva@tecal.udl.es

Tel. +34 973 702817

Fax. +34 973 702596

Dept Tecnologia de Aliments, Universitat de Lleida

Alcalde Rovira Roure 191, 25198 Lleida (Spain)

1 Abstract

2 The effect of virgin olive oil (VOO) enriched with its own polyphenols (PC) and/or thyme-
3 phenols on the protection of oxidative DNA damage and antioxidant endogenous enzymatic
4 system (AEES) were estimated in 33 hyperlipidemic subjects after the consumption of
5 VOO, VOO enriched with its own PC (FVOO), or complemented with thyme PC
6 (FVOOT). Compared to pre-intervention, 8-hydroxy-2'-deoxyguanosine (marker for DNA
7 damage) decreased in the FVOO intervention and to a greater extent in the FVOOT with a
8 parallel significant increase in olive and thyme phenolic biomarkers. Superoxide Dismutase
9 (AEES enzyme) significantly increased in the FVOO intervention and to a greater extent in
10 the FVOOT with a parallel significant increase in thyme phenolic metabolites. When
11 comparing all three oils, FVOOT appeared to have the greatest effect in protecting against
12 oxidative DNA damage and improving AEES. The sustained intake of a FVOOT improves
13 DNA protection against oxidation and AEES probably due to a greater bioavailability of
14 thyme PC in hyperlipidemic subjects.

15 Keywords:

16 virgin olive oil; phenol enrichment; thyme phenolics; hyperlipidemia; oxidative stress;
17 enzymatic antioxidants

18 INTRODUCTION

19 Virgin olive oil (VOO) is a typical food found in the Mediterranean diet and several
20 experimental and human studies have revealed that it has a unique phenolic composition
21 with relevant biological properties related to its anti-oxidant capacity and also modulating
22 gene expression ¹. The measurement of the antioxidant status of biological fluids is used as
23 an early warning sign of possible disease onset and also as an indicator of the status of the
24 antioxidant endogenous enzymatic system (AEES) ².

25 The polyphenol content of commercial VOOs is influenced by multiple agronomic and
26 technological factors. In this context, the enrichment of VOOs with its own phenolic
27 compounds (PC) is an interesting strategy to increase and standardize the daily intake of PC
28 in the real food matrix without increasing caloric intake. Additionally, flavoring olive oils
29 with herbs and spices can improve their PC profile. The leafy parts of thyme and its
30 essential oil have been used in foods for flavour, aroma, and preservation and also in
31 traditional medicines. Thyme is rich in phenolics, e.g., flavonoids, phenolic acids, and
32 monoterpenes ³. Thus, the enrichment of VOOs with complementary PC from thyme was
33 proposed as a novel approach to investigate the combined or synergic beneficial effects of
34 PC from different sources. In previous studies, we observed that when PC from olive and
35 thyme in a combined extract were administered to rats, an enhanced bioavailability of olive
36 PC occurred in the presence of thyme PC ⁴. In agreement with these findings, when the
37 volunteers from the VOHF Project (Virgin Olive oil and HDL Functionality (VOHF): a
38 model for tailoring functional food) ingested VOO enriched with own PC plus
39 complementary PC from thyme, an improved bioavailability of olive PC was also observed

40 ⁵. The combination of different PC sources might, therefore, be a promising approach to
41 improve not only the bioavailability but also a consequent enhancement of their biological
42 effects.

43 Antioxidant enzymes, such as superoxide dismutase (SOD), glutathione peroxidase
44 (GSHPx), and catalase (CAT), which are of endogenous origin and constitute the first line
45 of antioxidant defense, provide a real state of long-term defense against oxidative stress.
46 The activity of this first line of antioxidants may be modulated by dietary bioactive
47 compounds. Thus, PC provided by VOO can protect against systemic oxidation, which is
48 modulated by the main antioxidant endogenous enzymatic system (AEES) ⁶. The protection
49 of body cells and molecules such as DNA, proteins and lipids from oxidative damage could
50 be considered as a beneficial physiological effect. Different markers of oxidative damage or
51 repair to molecules should preferably be determined in the same study and could be useful
52 if appropriate techniques are used for its analysis ⁷. In this regard, mass spectrometry
53 determination of 8-hydroxy-2-deoxy-guanosin (oxidative damage to DNA), F2-
54 isoprostanes (oxidative damage to lipids) and methionine sulfoxide (oxidative damage to
55 proteins) are appropriate ⁸⁻¹⁰.

56 Our aim was to investigate the effect of two functional VOOs either enriched with its own
57 PC (FVOO) or complemented with thyme PC (FVOOT), on the protection of oxidative
58 stress, using urine and plasma oxidation biomarkers and erythrocyte antioxidant enzymes,
59 simultaneously with the detection of urine, plasma and erythrocyte phenolic metabolites in
60 hyperlipidemic subjects.

61 **MATERIALS AND METHODS**

62 **Study participants and experimental design.** The VOHF-sustained study was a
63 randomized, double-blinded, crossover, controlled trial with 33 hypercholesterolemic
64 volunteers (total cholesterol > 200 mg/dL) (19 men and 14 women), aged 35 to 80.
65 Exclusion criteria included the following: BMI > 35 kg/m², smokers (> 7 cigarettes/week),
66 athletes with high physical activity (> 3000 Kcal/day), diabetes, multiple allergies, intestinal
67 diseases, or any other disease or condition that would worsen adherence to the
68 measurements or treatment.

69 Subjects were randomized to one of 3 orders of administration of 25 mL/day of (i) virgin
70 olive oil (VOO; 2.88 mg total phenols/day), (ii) VOO enriched with its own PC (FVOO;
71 12.59 mg total phenols/day), and (iii) VOO enriched with both its own PC and thyme PC
72 (FVOOT; 12.10 mg total phenols/day). In the randomized, double blind, controlled
73 crossover design, intervention periods were of 3 weeks with a daily ingestion of 25 mL raw
74 VOO distributed among meals and preceded by a 2 week wash-out with a common olive oil
75 (Figure 1). The random allocation sequence was generated by a statistician, participant
76 enrolment was carried out by a researcher, and participants' assignment to interventions
77 according to the random sequence was done by a physician.

78 To avoid an excessive intake of antioxidants, such as PC, during the clinical trial period,
79 participants were advised to limit the consumption of polyphenol-rich food. A 3-day dietary
80 record was administered to the participants before and after each intervention period to
81 control their habitual diet throughout the study. A set of portable containers with the
82 corresponding 25 mL of VOO for each day of consumption was delivered to the participants
83 at the beginning of each VOO administration period. The participants were instructed to

84 return the containers to the center after the corresponding period in order to register the
85 amount consumed. Subjects with less than 80% of treatment adherence (≥ 5 full VOO or
86 FVOO or FVOOT containers returned) were considered non-compliance for this treatment.
87 24h/urine was collected in containers before each visit. Urine samples were stored at -80°C
88 prior to use. Blood samples were collected at fasting state. Plasma samples were obtained
89 by centrifugation of whole blood directly after being drawn and were preserved at -80°C
90 until use. Erythrocytes were obtained by centrifugation, washed twice with saline and
91 preserved at -80°C until use.

92 The VOHF study was approved by the Clinical Research Ethical Committee of the Institut
93 de Recerca Hospital del Mar (IMIM) (CEIC 2009/3347/I), and the study was listed on
94 ISRCTR.org, ISRCTN77500181. Protocols were according to the Helsinki Declaration and
95 good clinical practice guidelines of the International Conference of Harmonization (ICH
96 GCP), the trial was conducted according to extended CONSORT 2010 guidelines.

97 **Sample size and power analysis.** The sample size of 30 individuals allows at least 80%
98 power to detect a statistically significant difference among three groups of 3mg/dL of
99 HDL-C and a standard deviation of 1.9, using an ANOVA test and assuming a dropout rate
100 of 15% and a Type I error of 0.05.

101 **Preparation and characterization of VOO.** VOO with a low phenolic content (80mg total
102 phenols/kg oil) was used as a control condition in the intervention and as an enrichment
103 matrix for the preparation of the two phenol-enriched VOOs with the same amount of PC
104 (500mg total phenols/kg oil) but with different phenolic composition. FVOO was enriched
105 with its own PC by adding a phenol extract obtained from freeze-dried olive cake and

106 FVOOT was enriched with its own PC (50%) and complemented with thyme PC (50%)
107 using a phenol extract made up of a mixture of olive cake and dried thyme. FVOOT
108 contained 50% of olive PC (hydroxytyrosol derivatives) and 50% thyme PC (flavonoids,
109 phenolic acids and monoterpenes) (Table 1). The procedure for obtaining the phenolic
110 extracts and enriched oils had been previously developed ¹¹. For the wash-out period, a
111 commercial common olive oil kindly provided by Borges Mediterranean Group was used.
112 The total phenolic content of the VOO was measured with the Folin–Ciocalteu method ¹².
113 The phenolic profile of the VOOs was analyzed by high-performance liquid
114 chromatography coupled to tandem mass spectrometry (HPLC/MS/MS) using a previously
115 described method ¹³. Tocopherols and fatty acids in the VOOs were analyzed following the
116 procedure described by Morelló et al. ¹⁴ and the carotenoid content was analyzed as
117 previously described by Criado et al. ¹⁵.

118 **Lipid profile.** Blood samples were collected at fasting state at least 10 hours prior to the
119 study, at the commencement of the study and before and after each treatment. EDTA-
120 plasma glucose, total-cholesterol (TC), and triglyceride (TG) levels were measured using
121 standard enzymatic automated methods, in a PENTRA-400 autoanalyzer (ABX-Horiba
122 Diagnostics, Montpellier, France). HDL-C was measured as soluble HDL-C determined by
123 an accelerator selective detergent method (ABX-Horiba Diagnostics, Montpellier, France).
124 LDL-C was calculated by the Friedewald equation whenever TGs were less than
125 300mg/dL.

126 **LC-MS oxidative stress markers.** A 1290 UHPLC Series Liquid Chromatograph coupled
127 to a 6490 QqQ/MS (Agilent Technologies, Palo Alto, U.S.A.) was used for 8-hydroxy-2'-

128 deoxyguanosine (8-OHdG), Methionine (Met), Methionine sulfoxide (MetSO) and 8-iso
129 Prostaglandin F2 α (8-iso PGF2 α) quantification. Ionization was carried out by electrospray
130 ion source (ESI) and acquisition was done in multiple reaction monitoring (MRM) mode.
131 ESI and MRM conditions are summarized in Supplementary Table 1 for all the compounds.
132 Chromatographic separation in both 8-OHdG method and Met and MetSO methods was
133 performed in an Acquity UPLC BEH HILIC, 2.1x100mm, 1.8 μ m (Waters, Milford,
134 U.S.A.), at a flow rate of 0.4mL/min, using 50mM NH₄AcO in water (solvent A) and ACN
135 (solvent B). Elution gradient for the 8-OHdG method was 0-2min 100%B isocratic, 2-4min
136 80%B, 4-5min 80%B isocratic, 5-7min 20%B, 7-9min 20%B isocratic and 9-10min
137 100%B, applying a post run of 1.5 min, and injecting a sample volume of 2 μ L. Retention
138 time of 8-OHdG was at 4.37 min. Elution gradient for Met and MetSO was 0-1min 95%B
139 isocratic, 1-6min 20%B, 6-10min 20%B isocratic, and 10-11min 95%B, with a post run of
140 1.5min, and a sample volume injection of 5 μ L. Retention times of Met and MetSO were of
141 3.51 and 4.30min, respectively.

142 For the 8-OHdG quantification, an aliquot of 50 μ L of freshly thawed urine sample was
143 mixed with 20 μ L of 100ng/mL of 8OH-2'dOG-15N5 as internal standard in ACN. After a
144 vortex of 10 sec and centrifugation at 15000 rpm for 10min at 4°C, supernatant was
145 analyzed by liquid chromatography coupled to mass spectrometry (LC-MS).

146 For the Met and MetSO quantification, an aliquot of 50 μ L of freshly thawed plasma sample
147 was mixed with 25 μ L of 25 μ g/mL of L-methionine-13C,d3 as internal standard and 150 μ L
148 of ACN/H₂O 50mM NH₄AcO 95:5 (v/v). After a vortex of 10sec and centrifugation at
149 15000rpm for 10min at 4°C, supernatant was analyzed by LC-MS.

150 For the 8-isoPGF₂ α , the chromatographic separation was carried out in an Eclipse XDB-
151 C18, 2.1x150mm, 1.8 μ m (Agilent Technologies), at a flow rate of 0.4mL/min, using 0.2%
152 acetic acid in water (solvent A) and ACN (solvent B). Elution gradient was 0-2 min 0%B
153 isocratic, 2-10 min 50%B, 10-11 min 100%B, 13-14 min 100%B isocratic. A post run of
154 1.5 min was applied. Injected sample volume was of 20 μ L. Its retention time was at 9.97
155 min.

156 For the 8-iso PGF₂ α quantification, an aliquot of 250 μ L of freshly thawed urine sample
157 was mixed with 20 μ L of 100ng/mL of 8iso PSF₂ α -d₄ as internal standard in
158 water/methanol 2:1 (v/v) to protein precipitation. After a vortex of 10 sec, extraction was
159 done by the addition of 750 μ L of diethyl ether, agitation for 10 min at room temperature
160 and centrifugation at 4000rpm for 10 min at 4°C. A volume of 700 μ L of the upper organic
161 phase was dried under a nitrogen gas flow and resuspended in 50 μ L of water/methanol 2:1
162 (v/v). After vortex and centrifugation at 15000rpm at 4°C for 10 min, the supernatant was
163 analyzed by LC-MS.

164 In the quantification of samples, standard solutions at different levels of concentration were
165 used to obtain calibration curves, and compounds in the samples were quantified by
166 interpolating the analyte/IS peak abundance ratio in these curves.

167 **Antioxidant enzymes in erythrocytes.** Determination of the hemoglobin (Hb) content of
168 lysate erythrocytes was carried out by laser-impedance colorimetry. Superoxide dismutase
169 (SOD) activity in erythrocytes was performed following McCord and Fridovich
170 methodology¹⁶ (Ransel RS 125, Randox Laboratories, Crumlin, United Kingdom) and was
171 expressed in U/g of Hb. This method employs xanthine and xanthine oxidase to generate

172 superoxide radicals, which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
173 phenyltetrazolium chloride to form a red formazan dye. The SOD activity is then measured
174 by the degree of inhibition of this reaction. Glutathione peroxidase (GSH-Px) activity was
175 measured by a modification of the method of Paglia and Valentine ¹⁷ (Ransel RS 505,
176 Randox Laboratories, Crumlin, United Kingdom) and expressed in U/L. GSH-Px catalyses
177 the oxidation of Glutathione (GSH) by cumene hydroperoxide. Catalase (CAT) activity was
178 measured based on the method of Aebi ¹⁸ with slight modifications. Briefly, 70ml of
179 phosphate buffer, 50ml of erythrocyte lysate (5 mg protein per ml) and 50ml of 1% H_2O_2
180 were added in each well of a quartz microplate (Hellma, Müllheim, Germany). After
181 shaking for 1–2s in a plate reader (FisherScientific, Madrid, Spain), the absorbance at 240nm
182 was monitored for 1min in 15s intervals. The final value is expressed as U/mg protein.

183 **Analysis of phenolic metabolites in urine, plasma and erythrocytes.** The extraction of
184 the phenolic metabolites from urine and plasma samples was carried out as previously
185 reported ⁵. The PC from erythrocytes samples were extracted with the Solid Phase
186 Extraction (SPE) system using OASIS HLB 200mg cartridges (Waters Corp., Milford,
187 MA). The conditioning of the SPE cartridges was done by adding sequentially 2mL of
188 methanol and 2mL of Milli-Q water acidified at pH 2 with acetic acid. Extractions were
189 performed by loading 1mL of washed erythrocytes, which had previously been mixed with
190 3mL of distilled water and 20 μ L of phosphoric acid at 85% to break the bonds between the
191 proteins and PC. The loaded cartridges were washed with 1mL of Milli-Q water and 1mL
192 of methanol at 5%. Finally, the retained PC were eluted using 3mL of methanol, which was
193 evaporated to dryness and reconstituted with 100 μ L of methanol.

194 The phenolic metabolites in biological fluids were selected based on our previous work in
195 which olive and thyme PC intake biomarkers were defined⁵. Thus, hydroxytyrosol sulfate
196 (HTS; urine, plasma and erythrocytes) and hydroxytyrosol acetate sulfate (HTAS; urine and
197 plasma) were analyzed as VOO phenol metabolites. Hydroxyphenylpropionic acid sulfate
198 (HPPAS; urine, plasma and erythrocytes), thymol sulfate (TS; urine, plasma and
199 erythrocytes) and p-cymene-diol glucuronide (PCymeneDG; urine) were analyzed as thyme
200 phenol metabolites. The analysis of the phenolic metabolites was carried out by Ultra
201 Performance Liquid Chromatography (UPLC) coupled to tandem MS (MS/MS) based on
202 the method described by Rubió et al.⁵.

203 **Animals and experimental procedure.** Twenty Wistar rats were obtained from Charles
204 River Laboratories (Barcelona, Spain). They were separated into four groups of 5 rats in
205 each group (4 females and 1 male). Group 1: control diet (CON), group 2: secoiridoids
206 (SEC), group 3: secoiridoids combined with thyme phenols (SEC+THY) and group 4:
207 thyme phenols (THY). The diet preparation and characteristics is explained in more detail
208 in Supplementary Table 2. Rats were fed during 21 days at a dose of 5 mg of phenolic
209 compounds/kg rat weight/day. SEC extract and SEC+THY were the same phenolic extracts
210 used for the preparation of FVOO and FVOOT, respectively, as described previously³.
211 Additionally, THY extract was used to investigate the effect of a comparable phenolic dose
212 exclusively from thyme. The animal procedures were conducted in accordance with the
213 guidelines of the European Communities Directive 86/609/EEC regulating animal research
214 and approved by the local ethical committee (CEEA-Universitat de Lleida, reference 7675).
215 The rats were sacrificed by intracardiac puncture after isoflurane anaesthesia (IsoFlo,
216 Veterinarian Esteve, Bologna, Italy). After blood collection, the rats were perfused with an

217 isotonic solution of sodium chloride (NaCl) 0.9 % to remove the remaining blood irrigating
218 the tissues and their livers were excised. Tissue samples were stored at -80 °C and freeze-
219 dried.

220 **NF- κ B -DNA binding activity.** NF- κ B p65-DNA binding was assessed in rat hepatic
221 tissue lysate using a Cayman kit (Cat. No. 10007889). A specific double-stranded DNA
222 sequence containing the NF- κ B response element was immobilized in the wells of a 96-
223 well plate. NF- κ B contained in whole-cell extract from tissue binds specifically to the NF-
224 κ B response element and was detected by addition of specific primary antibody directed
225 against NF- κ B (p65). Addition of a secondary antibody conjugated to horseradish
226 peroxidase (HRP) provided sensitive colorimetric readout at 450nm. The activity of NF- κ B
227 p65-DNA binding was represented as relative absorbance at 450nm/ μ g of protein.

228 **Data analysis and statistical procedures.** Descriptive data were expressed as mean \pm
229 standard deviation and post-pre intervention changes were expressed as mean \pm 95%
230 confidence interval [95%CI]. Prior to all analyses, normality of data was assessed using
231 Shapiro–Wilk’s W test and those lacking a normal distribution were log-transformed to
232 achieve normality. Linear regression models were used to adjust post-intervention values
233 for pre-intervention values, age and sex. Comparisons among groups were analyzed by
234 General Linear Models. Paired T-test was used to test the post-pre intervention period
235 changes on oxidative biomarkers, AEEs and PC biomarkers. Differences were considered
236 statistically significant at $P < 0.05$. Data were analyzed by SPSS version 20.0 (SPSS, Inc.,
237 IBM, Armonk, NY, USA).

238 **RESULTS**

239 **Participants and compliance.** The study was conducted at IMIM-Hospital del Mar
240 Medical Research Institute (Barcelona, Spain) from April 2012 to September 2012 with 33
241 enrolled participants completing the intervention period. The participants' flow chart is
242 described in Figure 2 and a discontinued single intervention occurred in three volunteers
243 due to an investigator's decision. Participants had a BMI range indicative of normal weight
244 to overweight and they were normotensive and hyperlipidemic (total cholesterol >200
245 mg/dL) according to established criteria. All 33 participants had borderline-high values of
246 total cholesterol and LDL cholesterol. There were no statistically significant differences in
247 baseline characteristics of the participants among sequences 1, 2 and 3 (Table 2).
248 Compliance was monitored through the determination of biomarkers of intake analyzing
249 the phenolic metabolites in the subject's biological fluids (urine and plasma) and a
250 successful dietary intervention was guaranteed. No adverse side effects were reported by
251 participants during any of the study treatments.

252 **Olive oils characterization.** Table 1 shows the chemical characterization of VOO, FVOO
253 and FVOOT, including individual PC, fat soluble micronutrients and fatty acids
254 composition. Only the phenolic composition differed among the three VOOs as they
255 presented the same composition regarding fat-soluble micronutrients and fatty acids. In
256 comparison to VOO, FVOO was basically enriched with HT and its derivatives providing
257 8.5mg/25mL oil/day. FVOOT enrichment consisted of a mixture of HT and its derivatives
258 (4.3mg/25mL oil/day), phenolic acids (0.65mg phenols/25mL oil/day), flavonoids
259 (2.95mg/25mL oil/day) and monoterpenes (0.86mg/25mL oil/day). Thus, FVOOT
260 contained 50% of olive PC and 50% of thyme PC.

261 **Olive and thyme phenolic metabolites in biological fluids.** Results of the phenolic
262 metabolites in urine and plasma are presented in table 3 and 4, respectively. Apart from
263 urine and plasma, in the present work results of the phenolic metabolites detected in
264 erythrocytes are presented (Table 5). When comparing all three VOOs, metabolites derived
265 from olive PC were significantly higher in FVOO compared to VOO and FVOOT in urine,
266 plasma and erythrocytes (Table 3, 4 and 5). Regarding the post-pre intervention changes,
267 HTS and HTAS significantly increased after FVOO intervention in urine. HTAS was also
268 significantly increased in plasma after FVOO. No post-pre intervention changes in FVOOT
269 were observed in HT biomarkers in any biological fluid. The thyme phenolic metabolites
270 detected in urine, plasma and erythrocytes were HPPAS, TS and PCymeneDG (only
271 detected in urine). When comparing the three interventions HPPAS and TS levels were
272 significantly higher in the FVOOT group compared to the VOO and FVOO in all biological
273 fluids, and PCymeneDG also in urine (Table 3, 4 and 5). Regarding the post-pre
274 intervention changes, HPPAS, TS and PCymeneDG significantly increased after the
275 FVOOT. HPPAS appeared to be a clear erythrocyte biomarker for thyme phenolics, as it
276 was only detected after FVOOT intervention (Table 5).

277 **Effects of VOO PC enrichment on oxidative stress.** The outcome measurements of urine
278 oxidation biomarkers (8-iso PGF₂ α and 8-OHdG) and the post-pre intervention changes are
279 presented in Table 3. When comparing the three VOOs interventions, FVOOT presented
280 lower values of urinary 8-OHdG compared to FVOO and VOO after intervention. In
281 addition, urinary 8-OHdG was also significantly lower in FVOO than VOO. Urinary 8-iso
282 PGF₂ α did not differ when comparing the three VOOs interventions. Regarding the post-
283 pre intervention changes, urinary 8-OHdG decreased in the FVOO and to a greater extent in

284 the FVOOT intervention group. No post-pre intervention changes were observed in urinary
285 8-iso PGF₂ α . The outcome measurements of plasma % of MetSO in total Met and the
286 post-pre intervention changes are shown in Table 4. There were no differences between
287 groups of administered olive oils in plasma % of MetSO. Compared to baseline values, %
288 of MetSO was significantly increased in all groups (between 0.7-0.8 %).

289 **Effects of VOO PC enrichment on erythrocyte antioxidant enzymes.** The outcome
290 measurements of erythrocyte GSH-Px, SOD and CAT activities after the three VOOs
291 treatment and the post-pre intervention changes of each VOO group are shown in Table 5.
292 When comparing the three interventions, the activities of all enzymes were significantly
293 higher after the FVOOT and FVOO group compared to VOO. In addition, GSH-Px and
294 SOD were also significantly higher after the FVOOT group compared to the FVOO
295 ($P < 0.05$). Regarding the post-pre intervention changes, SOD activity significantly
296 improved after the FVOO intervention and significantly improved even to a greater extent
297 after the FVOOT one ($P < 0.05$). All the other measurements of antioxidant enzyme
298 activities did not differ between post-pre interventions.

299 **Animal experiment: NFkB-DNA binding activity.** Thyme supplementation in rat feed
300 (THY) significantly reduced the NFkB-DNA binding activity respect to control (CON)
301 (Figure 3). As shown in Figure 3, it appears that supplementation with olive oil PC (SEC)
302 and both thyme and olive oil PC (SEC+THY) starts a trend to reduced activity of NFkB,
303 which is established as significant when rats are only supplemented with thyme PC (THY).

304 **DISCUSSION**

305 Our study demonstrates that a sustained intake of FVOOT, which provided the same
306 amount of PC but different PC composition of FVOO, appeared to have a greater effect
307 against oxidative stress in hyperlipidemic subjects. VOO presented the highest 8-OHdG
308 values followed by FVOO and FVOOT, suggesting that FVOOT intervention provided
309 major protection against oxidative DNA damage.

310 The antioxidant protection was also reflected in the activity of antioxidant enzymes in
311 erythrocytes. In this sense, the SOD activity was also increased to a greater extent after the
312 FVOOT than the FVOO and VOO interventions with a parallel increase in thyme phenolic
313 metabolites detected both in urine and erythrocytes after FVOOT compared to FVOO. Our
314 data therefore provide the first level of evidence for an antioxidant DNA action and
315 antioxidant enzymatic induction through a combination of olive and thyme PC, after a
316 sustained consumption of real-life doses of olive oil in hyperlipidemic subjects.

317 The 8-OHdG is a major base product formed after DNA oxidative damage and has been
318 widely used as a DNA damage indicator in nutritional studies ¹⁹. Large amounts of 8-
319 OHdG are produced in mammalian cells, either as a by-product of normal oxidative
320 metabolism or as a result of exogenous sources of reactive oxygen species (ROS).
321 Increased levels of 8-OHdG in tissues represent a signal of a strong DNA damaging
322 stimulus or the specific deficient DNA repair mechanism ²⁰. Oxidative damage to the DNA
323 base produces a point mutation through an A-T substitution when incorporated into DNA,
324 causing mutagenesis and carcinogenesis ²¹. In a previous study the urinary excretion of
325 oxidation products of guanine, the most commonly used markers for DNA oxidation, was
326 not modified after 3-week consumption of 25mL olive oil with low (2.7mg/kg of caffeic

327 acid eq), medium (164 mg/kg), and high (366 mg/kg) PC in humans ²². In the same way,
328 no significant effect was detected in urinary excretion of DNA adducts after the
329 consumption of phenol-rich olive oil (PC content from 2.7 to 366 mg/kg) ²³. In contrast, a
330 decreased amount of 8-OHdG in urine after short-term consumption, 4-consecutive days
331 intervention of 25mL of three VOO, with low (10mg/kg of caffeic acid eq), medium
332 (133mg/kg), and high (486mg/kg) PC with a linear trend significantly correlated to the
333 content of PC ²⁴. Similarly, 30% reduction of oxidative DNA damage in peripheral blood
334 lymphocytes was observed after to substitute all types of fat and oils habitually consumed
335 with the study oil (50 g/d) for two periods of 8 weeks intervention on postmenopausal
336 women with VOO containing high amounts of phenols (592 mg total phenols/kg) compared
337 to those that consumed lowest levels (147 mg/kg) in postmenopausal women ²⁵. Our results
338 are in accordance with the latter 2 studies as a significant decrease in urinary 8-OHdG was
339 observed after the sustained consumption of phenol-enriched olive oils, FVOO and
340 FVOOT. Containing the same amount of PC, the 8-OHdG reduction was significantly 2-
341 fold higher in the FVOOT compared to the FVOO, this reduction may be attributed to the
342 different PC composition. Moreover, when comparing with VOO control group the 8-
343 OHdG reduction was significantly 10-fold higher in the FVOOT and 5-fold higher in the
344 FVOO.

345 In parallel to the oxidative DNA protection, the post-pre change values in 24h/urine of
346 thyme phenolic biomarkers (HPPAS, TS and PCymeneDG) significantly increased in
347 FVOOT group, which could be related to the significant reduction of 8-OHdG observed
348 after the FVOOT intake. Thus, the significant decrease in urinary 8-OHdG after FVOOT
349 consumption suggests that olive and thyme PC could act synergistically as bioactive

350 molecules protecting against oxidative DNA damage and improving oxidative systemic
351 balance as reflected also in the increase of erythrocyte SOD activity.

352 The post-pre intervention increase in erythrocyte SOD activity was about 14-fold higher in
353 the FVOOT group compared to the VOO and 2-fold higher compared to FVOO. These
354 data supports again that, olive and thyme PC may act synergistically as bioactive
355 molecules improving the erythrocyte antioxidant enzymatic system, in which SOD plays
356 the primary role ²⁶.

357 Erythrocytes, oxygen carriers with high polyunsaturated fatty acid content in their
358 membranes and high cellular concentration of hemoglobin, are particularly exposed to
359 oxidative damage. The hemoglobin released from erythrocytes is potentially dangerous
360 because when reacting with H₂O₂ it is converted into the oxidized forms with powerful
361 promoters of oxidative processes ²⁷. For this reason, newer functional agents, such as PC
362 from the diet can target oxidative stress in erythrocytes, as a valuable way to prevent or
363 delay the development of organ complications ²⁸.

364 In the present study, PC metabolites derived from olive or thyme were analyzed in
365 erythrocytes for the first time after an oral administration of olive oil in humans. HTS was
366 the only phenolic metabolite derived from olive PC detected in erythrocytes, whereas
367 HPPAS and TS were detected in erythrocytes as thyme phenolic metabolites. Regarding the
368 post-pre intervention changes, both erythrocyte HPPAS and TS significantly increased after
369 intervention in FVOOT group. In this regard, the parallel significant augmentation in the
370 SOD activity observed after the FVOOT intake could be attributed to the presence of these

371 metabolites in erythrocytes. This fact allows us to postulate that erythrocytes could be cell
372 targets for PC and its metabolites, which could exert an antioxidant effect in situ.

373 Thus, a clear parallelism appears between the modulations of antioxidant or oxidative
374 markers and PC metabolites observed in urine and in erythrocytes after VOO, FVOO or
375 FVOOT interventions.

376 In order to clarify the mechanistic pathways responsible for the higher protective
377 antioxidant effects observed after FVOOT compared to FVOO, a parallel experiment in
378 animals with the same phenolic compounds and similar doses administered to humans was
379 performed. It has been seen that hydroxytyrosol act as an inhibitor of NF- κ B activation, leading to
380 the inhibition of proliferation and promotion of apoptosis in human hepatocellular
381 carcinoma cells ²⁹. Furthermore, inhibiting NF- κ B activation reduces ROS production and
382 oxidative damage to lipids and DNA ³⁰. In our animal experiment, results revealed that
383 after supplementation with olive oil PC and both thyme and olive oil PC, a reduction trend
384 in the activity of hepatic NF- κ B is observed, which is established as significant when rats
385 are only supplemented with thyme PC. In that sense, the suppression of the NF- κ B pathway
386 by thyme PC could be sufficient to reduce the endogenous DNA damage produced
387 naturally by cells. Further studies are needed to verify this mechanistic pathway responsible
388 for the protective antioxidant effect observed in humans.

389 Considering the described results, it is surprising that % of MetSO in total Met was
390 increased in all groups after intervention. The three intervention groups have ingested oils
391 with different phenolic profile, therefore, this cannot explain the similar increase of the
392 MetSO observed in all groups. The exogenous antioxidants, including PC, are considered

393 “double-edged swords” in the cellular redox state and several studies of exogenous
394 antioxidants had shown controversial results, especially when administered at high doses
395 ^{31,32}. However, in present study the data obtained from of the three intervention groups after
396 a regular consumption of phenol-enriched VOO did not go globally in this direction,
397 despite the increase in % of MetSO. On the other hand, no changes of 8-iso PGF2 α were
398 observed in both the pre-post intervention levels and between VOO. As we are aware of the
399 limitations of the use of this biomarker, we have taken into account some important aspects
400 to use it in a reliable manner. We tried to prevent the ex vivo oxidation during processing
401 and storing of samples. In addition, the use of urine samples collected during 24 hours
402 globally reflect changes in lipid peroxidation and minimize the possible circadian variation
403 of 8-iso PGF2 α .

404 One of the strengths of the present study was its design. Randomized, controlled, clinical
405 trials were those able to provide the first level of scientific evidence. The crossover design,
406 in which each subject acts as the corresponding control, minimizes the inter-variability. In
407 addition, the fatty acid composition, vitamin E content and parental matrix of the three
408 olive oils were similar whereas the only difference was the PC profile and amount.

409 One potential limitation of the study was that although the trial was blinded, some
410 participants might have identified the type of olive oil ingested by its organoleptic
411 characteristics. Another limitation was the inability to assess potential synergies and
412 interactions among the VOOs and other diet components. Nevertheless, the controlled diet
413 followed throughout the trial should have limited the scope of these interactions.

414 In conclusion, the sustained intake of a phenol-enriched VOO with its own PC and
415 complemented with thyme PC improves DNA protection against oxidation and antioxidant
416 endogenous enzymatic activity probably due to a greater bioavailability of thyme phenolic
417 compounds in hyperlipidemic subjects.

418 REFERENCES

- 419 (1) Martín-Peláez, S.; Covas, M. I.; Fitó, M.; Kušar, A.; Pravst, I. Health effects of olive
420 oil polyphenols: recent advances and possibilities for the use of health claims. *Mol.*
421 *Nutr. Food Res.* **2013**, *57*, 760–771.
- 422 (2) Rabovsky, A.; Cuomo, J.; Eich, N. Measurement of plasma antioxidant reserve after
423 supplementation with various antioxidants in healthy subjects. *Clin. Chim. Acta*
424 **2006**, *371*, 55–60.
- 425 (3) Rubió, L.; Motilva, M. J.; MacIà, A.; Ramo, T.; Romero, M. P. Development of a
426 phenol-enriched olive oil with both its own phenolic compounds and complementary
427 phenols from thyme. *J. Agric. Food Chem.* **2012**, *60*, 3105–3112.
- 428 (4) Rubió L, Serra A, Chen CY, Macià A, Romero MP, Covas MI, Solà R, M. M. Effect
429 of the co-occurring components from olive oil and thyme extracts on the antioxidant
430 status and its bioavailability in an acute ingestion in rats. *Food Funct* **2014**, *5* (4),
431 740.
- 432 (5) Rubió, L.; Farràs, M.; de La Torre, R.; Macià, A.; Romero, M. P.; Valls, R. M.; Solà,
433 R.; Farré, M.; Fitó, M.; Motilva, M. J. Metabolite profiling of olive oil and thyme
434 phenols after a sustained intake of two phenol-enriched olive oils by humans:
435 Identification of compliance markers. *Food Research International*. 2014.
- 436 (6) Plestina-Borjan I, Katusic D, Medvidovic-Grubisic M, Supe-Domic D, Bucan K,
437 Tandara L, R. V. Association of age-related macular degeneration with erythrocyte
438 antioxidant enzymes activity and serum total antioxidant status. *Oxid Med Cell*
439 *Longev* **2015**, No. 804054.

- 440 (7) EFSA Panel on Dietetic Products Nutrition and Allergies (NDA)s. Guidance on the
441 scientific requirements for health claims related to antioxidants , oxidative damage
442 and cardiovascular health. *EFSA J.* **2011**, *9*, 1–13.
- 443 (8) Cooke, M. S.; Lunec, J.; Evans, M. D. Progress in the analysis of urinary oxidative
444 DNA damage. *Free Radic. Biol. Med.* **2002**, *33* (12), 1601–1614.
- 445 (9) Davies, S. S.; Roberts, L. J. F2-isoprostanes as an indicator and risk factor for
446 coronary heart disease. *Free Radical Biology and Medicine.* 2011, pp 559–566.
- 447 (10) Edrey, Y. H.; Salmon, A. B. Revisiting an age-old question regarding oxidative
448 stress. *Free Radical Biology and Medicine.* Elsevier Inc. 2014, pp 368–378.
- 449 (11) Rubió, L.; MacIà, A.; Valls, R. M.; Pedret, A.; Romero, M. P.; Solà, R.; Motilva, M.
450 J. A new hydroxytyrosol metabolite identified in human plasma: Hydroxytyrosol
451 acetate sulphate. *Food Chem.* **2012**, *134* (2), 1132–1136.
- 452 (12) Vázquez Roncero, A., Janer Del Valle, C., & Janer Del Valle, M. L. Determinación
453 de los polifenoles totales del aceite de oliva. *Grasas y Aceites* **1973**, *24* (6), 350.
- 454 (13) Rubió, L.; Serra, A.; Macià, A.; Borràs, X.; Romero, M. P.; Motilva, M. J.
455 Validation of determination of plasma metabolites derived from thyme bioactive
456 compounds by improved liquid chromatography coupled to tandem mass
457 spectrometry. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2012**, *905*, 75–84.
- 458 (14) Morelló, J. R.; Romero, M. P.; Motilva, M. J. Effect of the maturation of the olive
459 fruit on the phenolic fraction of drupes and oils from Arbequina, Farga, and Morrut
460 cultivars. *J. Agric. Food Chem.* **2004**, *52* (19), 6002–6009.
- 461 (15) Criado, M. N.; Romero, M. P.; Casanovas, M.; Motilva, M. J. Pigment profile and

- 462 colour of monovarietal virgin olive oils from Arbequina cultivar obtained during two
463 consecutive crop seasons. *Food Chem.* **2008**, *110* (4), 873–880.
- 464 (16) McCord, J. M.; Fridovich, I. Superoxide dismutase. An enzymic function for
465 erythrocyte (hemocuprein). *J. Biol. Chem.* **1969**, *244* (22), 6049–6055.
- 466 (17) Paglia DE, V. W. Studies on the quantitative and qualitative characterization of
467 erythrocyte glutathione peroxidase. *J Lab Clin Med* **1967**, *70* (1), 158.
- 468 (18) Aebi, H. [13] Catalase in vitro. *Methods Enzymol.* **1984**, *105* (C), 121–126.
- 469 (19) Halliwell, B. Why and how should we measure oxidative DNA damage in nutritional
470 studies? How far have we come? *Am. J. Clin. Nutr.* **2000**, *72* (5), 1082–1087.
- 471 (20) Sharma, H.; Kanwal, R.; Bhaskaran, N.; Gupta, S. Plant flavone apigenin binds to
472 nucleic acid bases and reduces oxidative DNA damage in prostate epithelial cells.
473 *PLoS One* **2014**, *9* (3).
- 474 (21) Jena, N. R.; Mishra, P. C. Formation of ring-opened and rearranged products of
475 guanine: Mechanisms and biological significance. *Free Radical Biology and*
476 *Medicine.* 2012, pp 81–94.
- 477 (22) Machowetz A, Poulsen HE, Gruendel S, Weimann A, Fitó M, Marrugat J, de la
478 Torre R, Salonen JT, Nyssönen K, Mursu J, Nascetti S, Gaddi A, Kiesewetter H,
479 Bäumler H, Selmi H, Kaikkonen J, Zunft HJ, Covas MI, Koenig CMachowetz A,
480 Poulsen HE, Gruendel S, We, K. C. Effect of olive oils on biomarkers of oxidative
481 DNA stress in Northern and Southern Europeans. *FASEB J* **2007**, *21* (1), 45.
- 482 (23) Hillestrøm, P. R.; Covas, M. I.; Poulsen, H. E. Effect of dietary virgin olive oil on
483 urinary excretion of etheno-DNA adducts. *Free Radic. Biol. Med.* **2006**, *41* (7),

- 484 1133–1138.
- 485 (24) Weinbrenner, T.; Fitó, M.; de la Torre, R.; Saez, G. T.; Rijken, P.; Tormos, C.;
486 Coolen, S.; Albaladejo, M. F.; Abanades, S.; Schroder, H.; et al. *Olive oils high in*
487 *phenolic compounds modulate oxidative/antioxidative status in men.*; 2004; Vol.
488 134.
- 489 (25) Salvini, S.; Sera, F.; Caruso, D.; Giovannelli, L.; Visioli, F.; Saieva, C.; Masala, G.;
490 Ceroti, M.; Giovacchini, V.; Pitozzi, V.; et al. Daily consumption of a high-phenol
491 extra-virgin olive oil reduces oxidative DNA damage in postmenopausal women. *Br.*
492 *J. Nutr.* **2006**, *95* (4), 742–751.
- 493 (26) Johnson, F.; Giulivi, C. Superoxide dismutases and their impact upon human health.
494 *Molecular Aspects of Medicine.* 2005, pp 340–352.
- 495 (27) Vandenberg, J. J. M.; Denkamp, J. A. F.; Lubin, B. H.; Roelofsen, B.; Kuypers, F. A.
496 Kinetics and Site Specificity of Hydroperoxide-Induced Oxidative Damage in Red-
497 Blood-Cells. *Free Radic. Biol. Med.* **1992**, *12* (6), 487–498.
- 498 (28) Silva, D. G. H.; Belini Junior, E.; De Almeida, E. A.; Bonini-Domingos, C. R.
499 Oxidative stress in sickle cell disease: An overview of erythrocyte redox metabolism
500 and current antioxidant therapeutic strategies. *Free Radical Biology and Medicine.*
501 2013, pp 1101–1109.
- 502 (29) Zhao, B.; Ma, Y.; Xu, Z.; Wang, J.; Wang, F.; Wang, D.; Pan, S.; Wu, Y.; Pan, H.;
503 Xu, D.; et al. Hydroxytyrosol, a natural molecule from olive oil, suppresses the
504 growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear
505 factor-kappa B pathways. *Cancer Lett.* **2014**, *347* (1), 79–87.

- 506 (30) Tilstra, J. S.; Robinson, A. R.; Wang, J.; Gregg, S. Q.; Clauson, C. L.; Reay, D. P.;
507 Nasto, L. A.; St Croix, C. M.; Usas, A.; Vo, N.; et al. NF- κ B inhibition delays DNA
508 damage-induced senescence and aging in mice. *J. Clin. Invest.* **2012**, *122* (7), 2601–
509 2612.
- 510 (31) Bouayed, J.; Bohn, T. Exogenous Antioxidants—Double-Edged Swords in Cellular
511 Redox State: Health Beneficial Effects at Physiologic Doses versus Deleterious
512 Effects at High Doses. *Oxidative Medicine and Cellular Longevity*. 2010, pp 228–
513 237.
- 514 (32) Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T. D.; Mazur, M.; Telser, J. Free
515 radicals and antioxidants in normal physiological functions and human disease. *Int.*
516 *J. Biochem. Cell Biol.* **2007**, *39* (1), 44–84.

517

518 **SUPPORTING INFORMATION**

519 ESI and MRM conditions are summarized in Supplementary Table 1 for all the compounds.

520 Diet characteristics of the animal experiment are detailed in Supplementary Table 2.

521

522 **ACKNOWLEDGEMENTS**

523 Borges Mediterranean Group for providing the common olive oil used in the study.

524

525 **FUNDING**

526 This study was supported by: the Ministerio de Economía y Competitividad (AGL2012-

527 40144-C03-02; AGL2012-40144-C03-01 and AGL2012-40144-C03-03 projects and,

528 AGL2009-13517-C03-01 and AGL2009-13517-C03-03 project), CIBEROBN, FPI

529 fellowship (BES-2010-040766), ISCIII and Departament de Salut joint contract

530 (CP06/00100).

FIGURE CAPTIONS

Figure 1. VOHF study design in human volunteers. This was a randomized, crossover, controlled trial with 30 hyperlipemic individuals comparing the effects of 3 types of virgin olive oil: control (VOO), enriched with its own phenolics (FVOO) and enriched not only with its own phenolics but also with phenolics from thyme (FVOOT).

Figure 2. VOHF Study flowchart.

Figure 3. Effect of phenolic compounds supplementation on NF κ B activity in whole-cell extract from rat liver after 21 days of feeding at a dose of 5 mg of phenolic compounds/kg rat weight/day. Control Standard feed (CON), Secoiridoids (SEC), Secoiridoid combined with thyme phenols (SEC+THY) and Thyme phenols (THY). p values: respect to CON. Values are shown as mean \pm SD.

TABLES

Table 1. Composition of the olive oils used in the study regarding phenolic compounds, fat soluble micronutrients and fatty acids profile.

	VOO	FVOO	FVOOT
PHENOLIC COMPOUNDS (mg/25 mL/day)			
hydroxytyrosol	0.01 ± 0.00	0.21 ± 0.02	0.12 ± 0.00
3,4-DHPEA-AC	n.d.	0.84 ± 0.06	0.39 ± 0.04
3,4-DHPEA-EDA	0.04 ± 0.00	6.73 ± 0.37	3.43 ± 0.29
3,4-DHPEA-EA	0.26 ± 0.04	0.71 ± 0.06	0.36 ± 0.03
Total HT derivatives	0.30	8.49	4.30
p-hydroxybenzoic acid	n.d.	0.02 ± 0.00	0.06 ± 0.00
vanillic acid	n.d.	0.07 ± 0.00	0.13 ± 0.01
caffeic acid	n.d.	0.00 ± 0.00	0.06 ± 0.00
rosmarinic acid	n.d.	n.d.	0.41 ± 0.03
Total phenolic acids	-	0.09	0.65
thymol	n.d.	n.d.	0.64 ± 0.05
carvacrol	n.d.	n.d.	0.23 ± 0.02
Total monoterpenes	-	-	0.86
luteolin	0.04 ± 0.00	0.18 ± 0.02	0.21 ± 0.02
apigenin	0.02 ± 0.00	0.06 ± 0.00	0.10 ± 0.00
naringenin	n.d.	n.d.	0.20 ± 0.02
eriodictyol	n.d.	n.d.	0.17 ± 0.01
thymusin	n.d.	n.d.	1.22 ± 0.09
xanthomicrol	n.d.	n.d.	0.53 ± 0.06
7-methylsudachitin	n.d.	n.d.	0.53 ± 0.09
Total flavonoids	0.06	0.23	2.95
pinoresinol	0.05 ± 0.00	0.12 ± 0.00	0.10 ± 0.05
acetoxipinoresinol	2.47 ± 0.19	3.66 ± 0.31	3.24 ± 0.28
Total lignans	2.52	3.78	3.34
FAT SOLUBLE MICRONUTRIENTS (mg/25 mL/day)			
α-tocopherol	3.27 ± 0.01	3.40 ± 0.02	3.44 ± 0.01
lutein	0.05 ± 0.00	0.06 ± 0.00	0.06 ± 0.00
β-cryptoxanthin	0.02 ± 0.00	0.03 ± 0.00	0.02 ± 0.00
β-carotene	0.01 ± 0.00	0.02 ± 0.00	0.02 ± 0.00
FATTY ACIDS (relative area %)			
Palmitic acid	11.21	11.20	11.21
Stearic acid	1.92	1.92	1.92
Araquidic acid	0.36	0.36	0.36
Behenic acid	0.11	0.11	0.11
Total saturated	13.75	13.74	13.75
Palmitoleic acid	0.70	0.70	0.69
Oleic acid	76.74	76.83	76.75

Gadoleic acid	0.27	0.27	0.27
Total monounsaturated	77.71	77.80	77.72
Linoleic acid	7.43	7.36	7.43
Timnodonic acid	0.36	0.36	0.35
Linolenic acid	0.43	0.43	0.43
Total polyunsaturated	8.22	8.15	8.22

Values provide the individual phenolic characterization of the olive oils expressed as means \pm SD of mg phenols/25 mL oil/day. Abbreviations: VOO: Virgin Olive Oil; FVOO: Functional Virgin Olive Oil enriched with its own phenolics; FVOOT: Functional Virgin Olive Oil enriched with both its own phenolics and phenolics from Thyme; 3,4-DHPEA-AC, 4-(acetoxyethyl)-1,2-dihydroxybenzene; 3,4-DHPEA-EDA, dialdehydic form of elenolic acid linked to hydroxytyrosol; 3,4-DHPEA-EA, oleuropein aglycone; n.d.: not determined.

Table 2. Baseline characteristics of the participants in the chronic consumption study.

	Sequence 1 (n=11)	Sequence 2 (n=11)	Sequence 3 (n=11)
Gender, <i>male/female</i>	7/4	7/4	5/6
Age, <i>years</i>	55.45 ± 7.84	55.18 ± 11.88	54.91 ± 12.57
Body weight, <i>kg</i>	84.45 ± 17.74	74.60 ± 18.49	74.75 ± 16.80
BMI, <i>kg/m²</i>	27.85 ± 4.71	26.33 ± 5.29	25.63 ± 3.68
SBP, <i>mm Hg</i> †	130 (106 – 166)	128 (96 – 151)	125 (104 – 153)
DBP, <i>mm Hg</i> †	72 (44 – 90)	72 (52 – 85)	68 (52 – 101)
Glucose, <i>mg/dL</i>	90.91 ± 10.53	93.00 ± 13.33	88.55 ± 11.63
Total cholesterol, <i>mg/dL</i>	218.82 ± 82	231.91 ± 32.70	228.36 ± 42.70
LDL cholesterol, <i>mg/dL</i>	142.45 ± 25.64	152.00 ± 28.45	150.80 ± 34.08
HDL cholesterol, <i>mg/dL</i>	53.39 ± 9.55	52.96 ± 12.82	52.78 ± 11.75
Tryglicerides, <i>mg/dL</i>	115.82 ± 32.49	134.36 ± 60.53	126 ± 86.68

Values are expressed as means ± SD; † Median (25th-75th percentile)

Sequence 1= FVOO, FVOOT and VOO; Sequence 2= FVOOT, VOO and FVOO;

Sequence 3= VOO, FVOO and FVOOT. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; VOO: Virgin Olive Oil; FVOO: Functional Virgin Olive Oil enriched with its own phenolics; FVOOT: Functional Virgin Olive Oil enriched with both its own phenolics and phenolics from Thyme

Table 3. Post-intervention values and changes from baseline of oxidation biomarkers and phenolic metabolite biomarkers in urine

	VOO (n=33)			FVOO (n=33)			FVOOT (n=33)		
	mean	(SD) [95%CI]	P-value Compared to Pre	mean	(SD) [95%CI]	P-value Compared to Pre	mean	(SD) [95%CI]	P-value Compared to Pre
Post-intervention Urine HT biomarkers									
HTS, $\mu\text{mol}/24\text{h}$ urine	9.6	(11.3)	0,660	18.0 ^a	(21.3)	0,007	12.1 ^b	(22.4)	0,350
HTAS, $\mu\text{mol}/24\text{h}$ urine	10.7	(8.2)	0,231	13.0 ^a	(7.5)	0,010	9.7 ^b	(5.3)	0,412
Changes in Urine HT biomarkers (Post-Pre)									
HTS, $\mu\text{mol}/24\text{h}$ urine	-0.8	[-4.7, 3.0]		8.1	[2.4, 13.8]		3.1	[-3.6, 9.7]	
HTAS, $\mu\text{mol}/24\text{h}$ urine	3.9	[-2.6, 10.5]		6.0	[1.6, 10.5]		2.6	[-3.9, 9.1]	
Post-intervention Urine Thyme biomarkers									
HPPAS, $\mu\text{mol}/24\text{h}$ urine	8.0	(4.3)	0,012	23.1 ^a	(6.7)	0,707	324.7 ^{a,b}	(73.6)	<0,001
TS, $\mu\text{mol}/24\text{h}$ urine	58.8	(39.0)	0,068	65.9	(59.4)	0,116	539.0 ^{a,b}	(287.9)	<0,001
PCymeneDG, $\mu\text{mol}/24\text{h}$ urine	0.1	(0.16)	0,107	1.6 ^a	(4.26)	0,351	53.4 ^{a,b}	(25.1)	<0,001
Changes in Urine Thyme biomarkers (Post-Pre)									
HPPAS, $\mu\text{mol}/24\text{h}$ urine	-22.3	[-39.2, -5.4]		-3.4	[-21.6, 14.9]		294.9	[187.6, 402.3]	
TS, $\mu\text{mol}/24\text{h}$ urine	-29.1	[-60.4, 2.3]		-21.8	[-49.4, 5.8]		470.2	[291.7, 648.7]	
PCymeneDG, $\mu\text{mol}/24\text{h}$ urine	-1.0	[-2.2, 0.2]		0.6	[-0.7, 1.8]		55.2	[35.2, 75.1]	
Post-intervention Urine Oxidation biomarkers									
8-OHdG, <i>nM</i>	15.3	(8.28)	0,796	12.9 ^a	(5.48)	0,015	10.6 ^{a,b}	(3.97)	0,008
8-iso PGF2 α , $\mu\text{g}/\text{L}$	0.46	(0.12)	0,574	0.45	(0.13)	0,359	0.45	(0.18)	0,493
Changes in Urine Oxidation biomarkers (Post-Pre)									
8-OHdG, <i>nM</i>	0.4	[-2.4, 3.1]		-2.0	[-3.7, -0.4]		-4.4	[-7.6, -1.2]	
8-iso PGF2 α , $\mu\text{g}/\text{L}$	-0.03	[-0.14, 0.08]		-0.03	[-0.09, 0.03]		-0.03	[-0.13, 0.06]	

Values are means and standard deviation (SD) for Post-intervention or 95% confidence interval [95%CI] for Changes Post-Pre. Post-intervention

comparison between administered olive oils; ^a: P<0.05 compared to VOO; ^b: P<0.05 compared to FVOO. P-value: Paired T-test comparison between

Post-intervention and Pre-intervention. Abbreviations: VOO: Virgin Olive Oil; FVOO: Functional Virgin Olive Oil enriched with its own phenolics; FVOOT: Functional Virgin Olive Oil enriched with both its own phenolics and phenolics from Thyme; 8-OHdG: 8-hydroxy-2'-deoxyguanosine; 8-iso PGF2 α : 8-iso Prostaglandin F2 α ; HTS: Hydroxytyrosol sulfate; HTAS: Hydroxytyrosol acetate sulfate; HPPAS: Hydroxyphenylpropionic acid sulfate; TS: Thymol sulfate; PCymeneDG: p-cymene-diol glucuronide.

Table 4. Post-intervention values and changes from baseline of oxidation biomarkers and phenolic metabolite biomarkers in plasma

	VOO (n=33)			FVOO (n=33)			FVOOT (n=33)		
	mean	(SD) [95%CI]	P-value Compared to Pre	mean	(SD) [95%CI]	P-value Compared to Pre	mean	(SD) [95%CI]	P-value Compared to Pre
Post-intervention Plasma HT biomarkers									
HTS, μM	0.84	(0.69)	0.547	1.52 ^a	(0.74)	0.099	1.23 ^{a,b}	(0.85)	0.088
HTAS, μM	0.97	(0.69)	0.475	1.73 ^a	(0.97)	0.002	1.14 ^b	(0.75)	0.206
Changes in Plasma HT biomarkers (Post-Pre)									
HTS, μM	0.13	[-0.30, 0.56]		0.75	[-0.15, 1.66]		0.50	[-0.08, 1.09]	
HTAS, μM	0.15	[-0.28, 0.59]		0.92	[0.38, 1.46]		0.39	[-0.23, 1.01]	
Post-intervention Plasma Thyme biomarkers									
HPPAS, μM	0.12	(0.15)	0.018	1.12 ^a	(0.62)	0.352	24.9 ^{a,b}	(13.9)	<0.001
TS, μM	0.84	(0.26)	0.002	1.61 ^a	(0.37)	0.221	26.7 ^{a,b}	(9.5)	<0.001
Changes in Plasma Thyme biomarkers (Post-Pre)									
HPPAS, μM	-1.70	[-3.1, -0.31]		-0.56	[-1.8, 0.7]		24.2	[13.6, 34.9]	
TS, μM	-1.89	[-3, -0.73]		-0.78	[-2.1, 0.5]		24.7	[16.3, 33.1]	
Post-intervention Plasma Oxidation biomarkers									
MetSO in total Met, %	5.4	(0.58)	0.033	5.6 ^a	(0.61)	0.006	5.5	(0.86)	0.016
Changes in Plasma Oxidation biomarkers (Post-Pre)									
MetSO in total Met, %	0.71	[0.06, 1.37]		0.85	[0.27, 1.43]		0.79	[0.6, 1.42]	

Values are means and standard deviation (SD) for Post-intervention or 95% confidence interval [95%CI] for Changes Post-Pre. Post-intervention comparison between administered olive oils; ^a: P<0.05 compared to VOO; ^b: P<0.05 compared to FVOO. P-value: Paired T-test comparison between Post-intervention and Pre-intervention. Abbreviations: VOO: Virgin Olive Oil; FVOO: Functional Virgin Olive Oil enriched with its own phenolics; FVOOT: Functional Virgin Olive Oil enriched with both its own phenolics and phenolics from Thyme; LDL: low-density lipoprotein; Methionine

SO: methionine sulfoxide; Met: methionine; HTS: Hydroxytyrosol sulfate; HTAS: Hydroxytyrosol acetate sulfate; HPPAS: Hydroxyphenylpropionic acid sulfate; TS: Thymol sulfate.

Table 5. Post-intervention values and changes from baseline of oxidation biomarkers and phenolic metabolite biomarkers in erythrocytes.


	VOO (n=33)			FVOO (n=33)			FVOOT (n=33)		
	mean (SD)	P-value		mean (SD)	P-value		mean (SD)	P-value	
		[95%CI]	Compared to Pre		[95%CI]	Compared to Pre		[95%CI]	Compared to Pre
Post-intervention Erythrocyte HT biomarkers									
HTS, nM	0.16 (0.67)	0.436	0.64 ^a (0.17)	0.171	1.55 ^{a,b} (1.28)	0.167			
Changes in Erythrocyte HT biomarkers (Post-Pre)									
HTS, nM	0.09 [-0.15, 0.33]		0.44 [-0.21, 1.10]		1.44 [-0.65, 3.53]				
Post-intervention Erythrocyte Thyme biomarkers									
HPPAS, nM	n.d. -		n.d. -		28.5 (13.6)	0.007			
TS, nM	n.d. -		1.07 (1.31)	0.328	10.26 ^b (1.92)	0.006			
Changes in Erythrocyte Thyme biomarkers (Post-Pre)									
HPPAS, nM	- -		- -		27.2 [8, 46.3]				
TS, nM	- -		0.87 [-0.93, 2.67]		10.25 [3.25, 17.3]				
Post-intervention Erythrocytes Endogenous antioxidants									
GPx activity, nmol/min/ml	72.1 (9.90)	0.835	72.8 ^a (9.51)	0.329	74.3 ^{a,b} (8.83)	0.228			
SOD activity, U/ml	716.6 (53.8)	0.875	739 ^a (76.7)	0.033	771 ^{a,b} (111.6)	0.043			
CAT activity, U/ml	111.7 (22.9)	0.142	115 ^a (22.3)	0.308	115.2 ^a (23.4)	0.760			
Changes in Erythrocytes Endogenous antioxidants (Post-Pre)									
GPx activity, nmol/min/ml	0.17 [-1.51, 1.85]		0.71 [-0.73, 2.14]		2.18 [-1.45, 5.82]				
SOD activity, U/ml	3.43 [-40.7, 47.6]		26.4 [2.14, 50.7]		48.1 [1.65, 94.6]				
CAT activity, U/ml	-6.49 [-15.28, 2.30]		-3.12 [-9.16, 2.93]		-2.17 [-16.65, 12.31]				

Values are means and standard deviation (SD) for Post-intervention or 95% confidence interval [95%CI] for Changes Post-Pre. Post-intervention

comparison between administered olive oils; a: P<0.05 compared to VOO; b: P<0.05 compared to FVOO. P-value: Paired T-test comparison between


Post-intervention and Pre-intervention. Abbreviations: VOO: Virgin Olive Oil; FVOO: Functional Virgin Olive Oil enriched with its own phenolics; FVOOT: Functional Virgin Olive Oil enriched with both its own phenolics and phenolics from Thyme; SOD: Superoxide Dismutase; CAT: Catalase; HTS: Hydroxytyrosol sulfate; HPPAS: Hydroxyphenylpropionic acid sulfate; TS: Thymol sulfate.


TOC Graphic



	1	2		3	4		5	6		7
	↓	↓		↓	↓		↓	↓		↓
Order 1 (n=11)	WO	X	WO	Y	WO	Z				
Order 2 (n=11)	WO	Y	WO	Z	WO	X				
Order 3 (n=11)	WO	Z	WO	X	WO	Y				

X = FVOO; Y = FVOOT; Z = VOO





OXIDATIVE STIMULI

Hyperlipidemia

ANTIOXIDATIVE STIMULI


Journal of Agricultural and Food Chemistry Page 44 of 43

VOO: Virgin Olive Oil (80ppm)

phenolics (500ppm)

FVOOT: Functional VOO enriched with its own

phenolics (250 ppm) and thyme phenols (250ppm)



ACS Paragon Plus Environment